Identifying heart tissue damage in patients with anthracycline-induced heart issues
Myocardial Fibrosis Identification in Patients With Anthracycline-induced Cardiotoxicity: Clinical and Prognostic Implications
This study is testing ways to see how much heart damage has been caused by anthracycline drugs in patients who have heart issues from their treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | European Institute of Oncology Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT06331806 on ClinicalTrials.gov |
What this trial studies
This interventional study focuses on patients who have developed anthracycline-induced cardiotoxicity during or after treatment with anthracycline drugs. The study aims to evaluate biochemical and imaging markers of myocardial fibrosis in these patients. Participants will undergo echocardiography to assess left ventricular ejection fraction and a cardiac magnetic resonance imaging with contrast to further evaluate heart tissue damage. The study is designed to provide insights into the extent of heart damage caused by the treatment.
Who should consider this trial
Good fit: Ideal candidates are patients who have experienced a reduction in left ventricular ejection fraction due to anthracycline therapy.
Not a fit: Patients under 18 years old or those with contraindications to contrast medium magnetic resonance imaging will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better identification and management of heart damage in patients treated with anthracycline drugs.
How similar studies have performed: Other studies have shown promise in using imaging techniques to assess cardiac damage, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who developed AIC during or after anthracycline-containing therapy assessed by LVEF valuation by echocardiography. Exclusion Criteria: * Age \<18 years * Contraindications to contrast medium magnetic resonance imaging
Where this trial is running
Milan
- European Institute of Oncology — Milan, Italy (Recruiting)
Study contacts
- Principal investigator: Daniela Cardinale, MD — European Institute of Oncology
- Study coordinator: Daniela Cardinale, MD
- Email: daniela.cardinale@ieo.it
- Phone: +39 0257489748
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.